Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of human sDR5-Fc recombinant fusion protein in preparation of drug for preventing and treating acute kidney injury

An acute kidney injury and fusion protein technology, applied in the field of recombinant proteins, can solve the problems of transmitting apoptosis signals, etc., and achieve broad application prospects, unique effects, and enhanced curative effects

Pending Publication Date: 2021-02-23
SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

sDR5 retains the activity of binding to TRAIL ligands, but cannot transmit apoptosis signals to cells, and can block the TRAIL-DR5-mediated apoptosis response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human sDR5-Fc recombinant fusion protein in preparation of drug for preventing and treating acute kidney injury
  • Application of human sDR5-Fc recombinant fusion protein in preparation of drug for preventing and treating acute kidney injury
  • Application of human sDR5-Fc recombinant fusion protein in preparation of drug for preventing and treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Design and recombination of recombinant human DR5-Fc expression sequence

[0047] After long-term accumulation of experience, the inventor constructed a recombinant fusion protein and fused human DR5 with Fc in various ways. The results of mass spectrometry analysis showed that most of the target proteins were cleaved at the N-terminal 11 amino acids (ITQQDLAPQQR). In order to express N The target protein with a relatively uniform terminal was finally screened to remove the intermediate connection sequence and 18 amino acids at the N-terminus on the basis of the commonly used signal peptide of the fusion protein, and named it sDR5-Fc (ZJ501-5). The plasmid was transiently transfected, and the expression supernatant was purified for mass spectrometry and activity analysis.

[0048] DNA sequence of ZJ501-5:

[0049] atgggtgtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcatgtccagcccctcagagggattgtgtccacctggacaccatatctcagaagacggtagagattgcatctcctg...

Embodiment 2

[0053] Example 2: Expression of Human sDR5-Fc Recombinant Protein and Detection of Physicochemical Properties

[0054] The sDR5-Fc / pL101 plasmid was transiently transfected into CHO.K1 cells with Lipofectamine2000, and the supernatant was collected for Dot Blot detection after 48 hours. The result was positive, see figure 2 .

[0055] To recover CHO.K1-S cells, press 5×10 5 / ml 10ml after resuspension, use FreeStyle TM CHO Expression Medium serum-free medium, and add Glutamine at a final concentration of 8mmol / L for culture, placed at 37°C in 8% CO 2 Shake the incubator at 120rpm for cultivation. When the number of cells>1×10 6 Subculture and add liquid to 30ml, maintain cell number 2-5×10 5 / ml, each subsequent passage and maintain the density to 2-5×10 5 / ml, CHO.K1-S needs to be subcultured more than three times.

[0056] The day before transfection, adjust the cell density to 5-6×10 5 / ml 100ml, placed at 37°C 8% CO 2 Shake the incubator at 120rpm for culture, a...

Embodiment 3

[0081] Example 3: Identification of biological activity of ZJ501-5

[0082] (1) Establish a commercial Trail killing activity detection method

[0083] Collect the Jurkat cells in the logarithmic growth phase, resuspend the cells with 10% FCS RPMI-1640 / DMEM after counting, and adjust the cell density to 8*10 4 / ml, 100ul / well was added to a 96-well cell culture plate, and placed in a 37°C, 8% carbon dioxide incubator for 20-24 hours.

[0084] Resuspend the commercial Trail in the above-mentioned complete culture solution containing actinomycin D (final concentration is 0.03ug / ml) at a final concentration of 500-1000ng / ml, and use the complete culture solution containing actinomycin D for 2 times Specific dilution commercial Trail, a total of 15-20 concentration gradients. The diluted sample was added to a 96-well cell culture plate at 100ul / well, and placed in an incubator for 18-22 hours. Add 20ul / well of freshly prepared 20:1 mixed MTS / PMS chromogenic solution, continue t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of human sDR5-Fc recombinant fusion protein in preparation of a drug for preventing and treating acute kidney injury. Nucleotide sequences for encoding the sDR5-Fcrecombinant fusion protein have: a) a base sequence shown as SEQ ID NO:1, or b) a sequence which is in complementary pairing with the SEQ ID NO:1, or c) a protein of a sequence of which encoding is the same as that of the nucleotide sequence of a or b, but the sequence is different from the nucleotide sequence of a or b due to the degeneracy of a genetic code; or an amino acid sequence of the sDR5-Fc recombinant fusion protein shown as SEQ ID NO:2, or a sDR5-Fc recombinant fusion protein with the amino acid sequence shown as SEQ ID NO:2, wherein one or more amino acids are substituted, but thebiological activity of the sDR5-Fc recombinant fusion protein is not changed; or amino acid sequences of the sDR5-Fc recombinant fusion protein shown as SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO: 6.

Description

technical field [0001] The invention relates to a recombinant protein, in particular to the application of a human sDR5-Fc recombinant fusion protein in the preparation of medicines for preventing and treating acute kidney injury. Background technique [0002] Acute kidney injury (AKI), formerly known as acute renal failure (ARF), refers to the clinical syndrome caused by the rapid decline of renal function caused by various etiologies. It can occur in people without previous kidney disease, and can also occur on the basis of existing chronic kidney disease. Compared with ARF, the proposal of AKI puts more emphasis on the importance of early diagnosis and early treatment of this syndrome. [0003] Acute kidney injury (AKI) is a clinical syndrome characterized by a sharp decline in glomerular filtration rate, which can significantly increase the length of hospital stay, medical costs, and mortality. In recent years, with the aging of the population and the increase of comor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P13/12C07K14/705A61K38/17
CPCA61K38/1793A61K39/395A61P13/12C07K14/70578C07K2319/30A61K2300/00
Inventor 万晓春沈恩允张青梅陈倩
Owner SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com